Education
About Us
Working with TipRanks
Follow Us
Aquestive Therapeutics (AQST)
NASDAQ:AQST
Total Valuation
Aquestive Therapeutics has a market cap or net worth of $271.90M. The enterprise value is $375.06M.
Market Cap$271.90M
Enterprise Value$375.06M
Share Statistics
Aquestive Therapeutics has 98,871,370 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding98,871,370
Owned by Insiders13.55%
Owned by Institutions0.24%
Financial Efficiency
Aquestive Therapeutics’s return on equity (ROE) is 0.73 and return on invested capital (ROIC) is -37.02%.
Return on Equity (ROE)0.73
Return on Assets (ROA)-0.44
Return on Invested Capital (ROIC)-37.02%
Return on Capital Employed (ROCE)-0.37
Revenue Per Employee405.36K
Profits Per Employee-310.82K
Employee Count142
Asset Turnover0.57
Inventory Turnover2.96
Valuation Ratios
The current PE Ratio of Aquestive Therapeutics is -7.00. Aquestive Therapeutics’s PEG ratio is -0.02.
PE Ratio-7.00
PS Ratio5.51
PB Ratio-5.13
Price to Fair Value-5.13
Price to FCF-8.60
Price to Operating Cash Flow-8.63
PEG Ratio-0.02
Income Statement
In the last 12 months, Aquestive Therapeutics had revenue of 57.56M and earned -44.14M in profits. Earnings per share was -0.51.
Revenue57.56M
Gross Profit39.69M
Operating Income-30.77M
Pretax Income-44.15M
Net Income-44.14M
EBITDA-26.62M
Earnings Per Share (EPS)-0.51
Cash Flow
In the last 12 months, operating cash flow was -35.76M and capital expenditures -159.00K, giving a free cash flow of -35.92M billion.
Operating Cash Flow-35.76M
Free Cash Flow-35.92M
Free Cash Flow per Share-0.36
Dividends & Yields
Aquestive Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.81
52-Week Price Change-27.48%
50-Day Moving Average2.85
200-Day Moving Average3.79
Relative Strength Index (RSI)53.09
Average Volume (3m)1.36M
Important Dates
Aquestive Therapeutics upcoming earnings date is May 6, 2025, TBA Not Confirmed.
Last Earnings DateMar 5, 2025
Next Earnings DateMay 6, 2025
Ex-Dividend Date―
Financial Position
Aquestive Therapeutics as a current ratio of 4.68, with Debt / Equity ratio of -63.18%
Current Ratio4.68
Quick Ratio4.36
Debt to Market Cap0.12
Net Debt to EBITDA1.26
Interest Coverage Ratio-1.83
Taxes
In the past 12 months, Aquestive Therapeutics has paid -14.00K in taxes.
Income Tax-14.00K
Effective Tax Rate<0.01
Enterprise Valuation
Aquestive Therapeutics EV to EBITDA ratio is -10.34, with an EV/FCF ratio of -7.66.
EV to Sales4.78
EV to EBITDA-10.34
EV to Free Cash Flow-7.66
EV to Operating Cash Flow-7.70
Balance Sheet
Aquestive Therapeutics has $71.55M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$33.54M billion.
Cash & Marketable Securities$71.55M
Total Debt$0.00
Net Cash-$33.54M
Net Cash Per Share-$0.34
Tangible Book Value Per Share-$0.69
Margins
Gross margin is 68.95%, with operating margin of -53.46%, and net profit margin of -76.68%.
Gross Margin68.95%
Operating Margin-53.46%
Pretax Margin-76.70%
Net Profit Margin-76.68%
EBITDA Margin-46.24%
EBIT Margin-47.49%
Analyst Forecast
The average price target for Aquestive Therapeutics is $8.15, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$8.15
Price Target Upside185.96% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast13.80%
EPS Growth Forecast-389.41%